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Purpose: Predictive genetic testing of relatives of known myocilin (MYOC) gene 
mutation carriers is an appropriate strategy to identify individuals at risk for 
glaucoma. It is likely to prevent irreversible blindness in this high-risk group because 
this treatable condition might otherwise be diagnosed late. The Australian and New 
Zealand Registry of Advanced Glaucoma has established genetic testing protocols for 
known glaucoma genes, including MYOC. 
Methods: Through the Australian and New Zealand Registry of Advanced Glaucoma, 
we investigated the experience of 40 unaffected individuals who had undergone 
predictive genetic testing for MYOC mutations through questionnaires. 
Results: The main motivations for being tested were (i) to make appropriate 
interventions and (ii) to reduce uncertainty. All our respondents perceived strong 
benefits, either medical or emotional, in being tested. However, different concerns 
were raised by the respondents that need to be addressed during counseling. Greater 
family awareness was reported by the majority of the respondents, and the ability to 
provide information to children was a strong motivation for being tested. 
Conclusion: This study provides valuable information on the personal and familial 
impacts of having predictive genetic testing for glaucoma, which will help health 
professionals to better address the issues faced by patients and provide them adequate 
support. 
Key Words: genetic counseling; glaucoma; MYOC; predictive genetic testing; POAG 
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With the development of new technologies and a better understanding of the genetics 
of diseases, genetic testing is becoming increasingly available. Predictive genetic 
testing is now possible for treatable conditions such as glaucoma. Glaucoma is a 
progressive optic neuropathy that when untreated may cause irreversible blindness; it 
affects 60 million people worldwide.
1
 There are strong medical benefits in favor of 
predictive genetic testing for primary open-angle glaucoma (POAG; OMIM no. 
137760), the most common type of glaucoma. Half of all cases go undiagnosed
2,3
 
because the early stages of the condition are often asymptomatic, and appropriate 
therapeutic interventions can prevent or minimize glaucoma-induced blindness.
4-6
 As 
a result, predictive genetic testing is an attractive goal to identify presymptomatic at-
risk individuals, which allows them to be educated about their risks and options 
before the onset of the condition and to receive appropriate management to prevent or 
at least minimize the vision loss that would have otherwise occurred. 
Mutations in the myocilin gene (MYOC, OMIM no. 601652), which are strongly 
associated with POAG, are transmitted in an autosomal dominant fashion and cause 
glaucoma at a younger age than is seen in the general population.
7,8
 The most 
common mutation, Gln368X, has a mean age at diagnosis in the early 50s,
8,9
 whereas 
other mutations, such as Pro370Leu, can be associated with an age at diagnosis as 
early as the teens.
10,11
 Detecting a mutation in an unaffected individual does not 
predict the age of onset, the severity, or the progression of the condition but puts the 
person at a very high risk of developing glaucoma in his/her lifetime. 
Because POAG is a treatable condition, predictive genetic testing is usually well 
accepted.
12
 Although the medical benefits have been well studied, little is known 
about the internal motivations and the experience of individuals undergoing predictive 
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testing for MYOC mutations. Decisions for undergoing genetic testing are usually 
driven by social and personal factors. These can range from personal experience with 
glaucoma in the family and knowledge of glaucoma and related treatment options to 
personality- and health-related locus of control. Knowledge about individuals’ 
experiences of predictive genetic testing is essential to provide adequate counseling 
and support to people who have been tested or who are considering being tested. In 
this study, we examined the motivations, the perceived benefits, and the feelings and 
concerns of individuals who had undergone predictive genetic testing for MYOC 
mutations. 
 
MATERIALS AND METHODS 
Recruitment 
Participants were recruited through the Australian and New Zealand Registry of 
Advanced Glaucoma (ANZRAG)
13
. Ethics approval was obtained from the Southern 
Adelaide Clinical Human Research Ethics Committee. In an antecedent study, 
potential participants with a definite diagnosis of glaucoma referred by their eye 
specialist were initially screened for MYOC mutations
8
. Genetic testing was then 
made available to all adult first-degree relatives of individuals confirmed as carrying a 
MYOC mutation. Because MYOC mutations display very high penetrance but some 
inter- and intrafamilial variability, we recommended that all at-risk adult relatives be 
offered genetic testing regardless of their age.
14
 To promote autonomous and 
voluntary decisions, relatives interested in being genetically tested had to contact the 
ANZRAG registry of their own volition. At the initial contact, a trained genetic 
counselor (E.S.) reviewed the testing process and the implications with the individual. 
Written informed consent was obtained, and DNA was extracted from a blood sample. 
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The test results were provided directly to the participants and, if nominated, an eye 
specialist. When the familial mutation was identified, a referral to a local 
ophthalmologist was facilitated. 
Our cohort comprised family members of individuals carrying a MYOC mutation, 
aged 18 years and older, who had consented to genetic testing for glaucoma and had 
already obtained their test result. A questionnaire was posted to each of them, 
regardless of the outcome of the test. After 1 month, individuals who did not return 
their questionnaire were contacted as a reminder and were given the opportunity to 
complete it over the phone. 
Questionnaire 
The questionnaire collected data relating to sociodemographic variables, perceived 
risks and feelings before being tested, perceived benefits and disadvantages of being 
tested, personal impact of the result, and familial impact of the results. 
Sociodemographic questions included gender, age, marital status, number and age of 
children, and education level. For analysis, we chose to categorize respondents into 
age groups, comparing those aged 40 years and younger with those older than 40 
years. The cutoff point of 40 years was selected based on the knowledge that those 
older than 40 years have a higher likelihood of developing glaucoma and therefore 
may have different motivations for undergoing genetic testing than younger 
respondents.  The perceived lifetime risk of developing glaucoma and the perceived 
risk of carrying the familial mutation were measured using four alternatives choices 
(highly unlikely, unlikely, likely, and highly likely). Responses of (i) highly unlikely 
and unlikely and (ii) likely and highly likely were then combined to create a 
dichotomous variable for analysis. The perceived severity of glaucoma was assessed 
on a scale of 1-5, with 1 being considered not severe and 5 being considered very 
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severe. The motivations for engaging in genetic testing were explored through 
multiple-choice responses. In free-response questions, participants were asked about 
the perceived benefits and disadvantages of the test, their concerns and fears with 
regard to glaucoma before and after the test, their initial reaction after finding out their 
test result, their positive and negative feelings associated with the result, and their 
level of satisfaction with the testing. Finally, respondents were asked about the 
experience within their family, including communication and disclosure patterns to 
children and other relatives, and any wider impact that their testing had on the family 
as a whole. 
Statistical Analyses 
Statistical analyses were conducted on all quantitative data using the Statistical 
Package for the Social Sciences, version 19 (SPSS, Chicago, IL). Significance was set 
at P < 0.05. Comparisons across demographic groups were made using χ2 tests for 
independence. Analysis of qualitative responses was undertaken in Microsoft Excel, 
with similar responses categorized together in frequency tables. 
 
RESULTS 
Demographic Data 
We have previously shown that MYOC mutations account for 4.2% of advanced 
POAG patients.
8
 In this study, we evaluated 18 MYOC-positive families, which 
comprised 82 at-risk relatives. The questionnaire was sent to the 52 (63%) participants 
who had requested to be tested and had received their MYOC test result; it was 
completed and returned by 43 respondents (83%) from 17 families. Three respondents 
were excluded from our analysis because they had already been diagnosed with 
glaucoma before being tested and thus their motivations and emotional reactions to 
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their results were likely to differ from those who did not have a glaucoma diagnosis. 
The demographics of nonresponders and those excluded due to previous diagnosis did 
not differ significantly from those of the included participants on any demographic 
measures (all P > 0.70). 
The demographic data of the 40 included respondents are shown in Table 1. The 
average age of the respondents was 46.6 ± 16.1 years old (range 18-87). Twenty-two 
respondents (55%) had tested positive for the MYOC gene. The MYOC mutations 
observed among the 18 families approached (Gln368X, Trp286Arg, Trp373X, and 
Thr377Met) were all of comparable severity. Three at-risk individuals younger than 
40 years displayed a combination of two mutations (Gln368X and Thr377Met) 
associated with a more severe phenotype in one family.
15
 
Risk perception and intentions regarding genetic testing 
Before being tested, half (20/40) of the respondents perceived their risk of developing 
glaucoma as being likely, or highly likely, and almost three quarters (28/40, 70%) 
perceived their risk of carrying the familial mutation as being likely or highly likely. 
Respondents believed glaucoma to be a moderately severe disorder, giving it an 
average severity score (on a scale of 1-5) of 3.6 ± 1.2. The perceived severity of 
glaucoma and the perceived risk of developing glaucoma or of carrying the familial 
mutation were not influenced by gender, age, education, carrier status, or the tested 
MYOC mutation (P > 0.20 for all). 
The motivations for individuals to undergo testing are summarized in Table 2. A 
significant interaction between respondent age group and motivations for having the 
genetic testing was found. Those older than 40 years of age reported that they had 
testing in order to provide information to their children about their risk of developing 
glaucoma significantly more often than younger respondents (χ² = 4.263, P = 0.039). 
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However, this difference was no longer significant when data for just those 
respondents with children was analyzed (P = 0.287) because older respondents had 
children more often than younger ones. Neither gender nor education nor the tested 
MYOC mutation influenced respondents’ motivations for being tested (P > 0.10 for all 
motivations). 
Perceived benefits and disadvantages of genetic testing 
All respondents considered predictive genetic testing for glaucoma useful. They 
described advantages of predictive testing for glaucoma, on the whole, more often 
than disadvantages. The main benefit reported by the respondents was the availability 
of monitoring for early detection and prevention of glaucoma-induced visual loss. The 
only disadvantage mentioned was that if identified as a carrier, they would have to 
live with the knowledge of being at increased risk of developing glaucoma. 
Respondents’ reactions and feelings 
The main initial reaction of noncarriers was happiness and relief, whereas carriers 
experienced a range of different emotions (Table 3). Positive feelings expressed by 
carriers were the awareness and the accompanying ability to act and therefore help 
reduce the impact of glaucoma, in addition to the possibility of providing better 
information to their children. Negative feelings and concerns of carriers were various 
and are summarized in Table 4. Three carriers expressed feelings of guilt. One 
noncarrier expressed mixed feelings because a sibling was found to have the familial 
mutation when she did not. Regardless of their test results, all respondents were 
satisfied with their decision to be tested. 
Impact on family 
Almost all of the respondents had discussed having genetic testing with their family 
(36/40, 90%) and had discussed their genetic result with them (38/40, 95%). The 
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majority of the respondents who had children had discussed their result with them 
(18/31, 58%). Respondents were significantly less likely to discuss positive results 
with their children if they were younger than 18 years old (χ² = 4.74, P = 0.029).  
Almost all respondents with adult children (13/14, 93%) communicated their results 
to them, whereas a minority with minor children did so (5/17, 29%). However, 67% 
(8/12) of carriers who did not discuss their results with their minor children had 
selected the provision of information to children as a motivation for being tested. 
Finally, the majority of respondents (30/40, 75%) reported increased awareness in the 
family regarding glaucoma risks and genetic testing. 
 
DISCUSSION 
Genetic testing for POAG has been available since the discovery of the MYOC gene 
in 1997.
16
 Even though MYOC mutations account only for 3-4% of all POAG cases,
7,8
 
relatives of MYOC carriers have had the opportunity to be screened and become 
educated about their glaucoma risk; moreover, they have been able to benefit from 
early prevention and management. However, there is a paucity of literature on the 
decision-making process and the impact of predictive genetic testing on individuals 
with treatable eye conditions such as glaucoma. In comparison, studies on inherited 
cancers have thoroughly evaluated patients’ motivations, family communication, and 
experience with predictive testing
17-20
. Inherited cancers differ from glaucoma in that 
they are life-threatening and require invasive interventions.
17,21
 However, both 
inherited cancers and glaucoma can be of juvenile or adult onset, have treatment 
options, and have an incomplete but strong penetrance; moreover, associated genetic 
testing has proven to have clinical validity for both conditions. We therefore used the 
literature on inherited cancers to draw parallels with our results. 
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Several theoretical models have been created in attempting to predict health 
behaviors. The Health Belief Model
22
 postulates that the higher the perceived 
susceptibility to and the perceived severity of the condition, and the higher the 
perceived effectiveness in taking actions, the more the person will engage in health 
behaviors.
21,23
 Our findings show that the majority of individuals who chose to be 
tested had a high perceived risk of having the familial mutation before being tested 
and considered glaucoma to be a serious medical condition. Some previous studies on 
inherited cancers have shown that individuals are more likely to be tested if their 
perceived risk, not their actual risk, of cancer was high.
17,18,24
 
A previous study on inherited cancers found that the perceived benefits component 
was the most powerful variable in explaining interest in predictive testing.
21
 Another 
study identified two clusters of motives: one included perceived health benefits (early 
detection, prevention, and control), and the other included perceived emotional 
benefits (reassurance, reduction of uncertainty, and emotional preparation).
23
  
Similarly, in our study, taking appropriate medical interventions and the reduction of 
uncertainty were the two most-often-selected motivations for undertaking genetic 
testing, and the main reported benefit was monitoring for early detection.  
A range of emotions were expressed by carriers of MYOC mutations after genetic 
results communication. These individuals were concerned about losing their vision, 
the potential impact on insurance, the transmission of the mutation to children, and the 
efficacy of interventions in treating glaucoma. Three carriers and one noncarrier also 
reported feelings of guilt. It is valuable to understand these concerns in order to better 
address them during counseling. Our findings show that people who undertake 
predictive genetic testing for MYOC mutations have no regrets with regard to being 
tested and are satisfied with their decision, regardless of their result. Healey et al. had 
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previously reported the acceptability of genetic testing for MYOC glaucoma among 
the members of one very large affected Australian family.
12
 
Greater family awareness following genetic testing was reported by the majority of 
the respondents. Recommendation by a family member was a major motivator for 
being tested. Almost all respondents disclosed their results to their family, regardless 
of their genetic result, and most of them even talked about the testing process before 
knowing their results, consistent with studies on hereditary cancers.
25,26
 All 
respondents with adult children, except one, disclosed their genetic result. The 
individual who did not was a noncarrier, and we postulate that the person did not 
think it useful to discuss the result with her children because there was no increased 
risk of developing glaucoma. Respondents with minor children were less likely to 
communicate their genetic result to them. However, the majority of the respondents 
who tested positive but did not share their results with their children had indicated that 
providing their children with information was a motivation for them to be tested, and 
so it is likely they will pass on this information when the children are older. Previous 
studies on families with inherited breast and ovarian cancers showed that the majority 
of parents (70-80%) discussed their genetic result with children of adult age, 
regardless of their carrier status
27,28
 and the age of the children was positively 
associated with communication. Most parents who did not disclose their result did so 
because they thought their children were too young or immature. Predictive testing is 
not offered to individuals younger than 18 years, unless the family age of onset is 
known to be at less than 18 years and there is an immediate medical benefit to test.
29
 
However, without offering genetic testing, young children can still benefit from 
learning the family’s carrier situation and therefore their potential risk. Genetic 
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counselors can help parents in providing information to children while respecting their 
decisions and family dynamics. 
There are some limitations to our study. Our sample is relatively small and our results 
might be skewed because our cohort reflects the motivations and concerns of 
individuals who decided to be tested. Further research in larger cohorts is required on 
the long-term perceived benefits and satisfaction of tested individuals, in addition to 
research on the at-risk relatives in our investigated families who did not request 
predictive MYOC testing. It also appears that people 40 years and younger who had 
received a negative result were less likely to respond to our invitation to participate 
and therefore our data were skewed to include an overrepresentation of individuals in 
this age group who had MYOC gene mutations. Although we do not make contact 
with the relatives’ clinicians before the test, we cannot exclude that some relatives 
talked to their clinician before contacting us and that this might have influenced their 
decision to be tested or not. The fact that some individuals come from the same family 
could be another bias as it might create some familial clustering effects. The MYOC 
mutations identified among our respondents were of comparable severity and did not 
seem to have affected the responses. However, one family displayed two MYOC 
mutations and a more severe phenotype, and we acknowledge that this has the 
potential to have skewed the results with regard to motivations and psychological 
topics. Finally, this was a retrospective study asking participants to recall their 
feelings before genetic testing. Recall of events can be biased and may be influenced 
by the length of time elapsed between disclosure of results and administration of the 
questionnaire, as well as being affected by the test results. A two-part questionnaire 
gathering data both before and after respondents receive their results would control 
for this. However, our analysis showed no association between the carrier status and 
13 
 
the perceived risks or the different motivations for being tested, suggesting that recall 
bias did not have had a large impact on the results. 
Despite these limitations, this study provides valuable preliminary findings on the 
motivators of asymptomatic individuals toward predictive genetic testing for POAG, 
and the personal and familial impacts of such testing. The acceptability of such an 
approach had been reported previously in an Australian family,
12
 but, to our 
knowledge, this is the first study to address the motivations, feelings, and concerns of 
individuals as applied to a whole population rather than within a single large family. 
We demonstrate that the testing process increases awareness about glaucoma among 
relatives, especially children of adult age, of those tested. This is important because 
these individuals are at risk of having inherited the familial mutation and can greatly 
benefit from preventive measures. We show that, similar to individuals who chose to 
have predictive testing for inherited cancers
20
, individuals who chose to have 
predictive testing for glaucoma perceived strong benefits, either medical or emotional, 
in being tested and may represent a selected group of individuals more likely to be 
able to cope with genetic results. Our cohort expressed strong satisfaction with their 
choice, and few people reported concerns or fears associated with genetic testing. 
However, one should not conclude from these findings that these individuals do not 
need support. Pretest genetic counseling needs to address, among other things, 
participants’ motivations for testing, perceived risks and benefits, potential concerns, 
and family dynamics. Posttest genetic counseling may need to focus more on 
associated feelings of guilt, regardless of the genetic result. 
Our findings are valuable for health professionals involved in the genetic testing 
process and the management of carriers; these health professionals need to be 
sensitive to the differences in personal concerns and intentions toward predictive 
14 
 
testing. Such results will help them in providing better support and in addressing the 
relevant medical, psychological, and familial issues with patients undergoing 
predictive genetic testing for POAG. 
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Table 1. Descriptive characteristics of the respondents 
 n (%) 
Age (years)  
18-40 15 (37.5) 
>40 25 (62.5) 
Gender  
Male 19 (47.5) 
Female 21 (52.5) 
Marital status  
Single 8 (20.0) 
Married/de facto 28 (70.0) 
Divorced/separated 2 (5.0) 
Widowed  2 (5.0) 
Children  
No 9 (22.5) 
Yes 31 (77.5) 
  <18 years old 17 (54.8) 
  ≥18 years old 14 (45.2) 
Education level  
Primary School 6 (15.0) 
High school 10 (25.0) 
Technical College 5 (12.5) 
University 18 (45.0) 
Not specified 1 (2.5) 
 
Table 2. Individuals’ motivations for being tested.  
 n (%) 
Motivations for being tested  
Take appropriate interventions 32 (80.0) 
Remove uncertainty 27 (67.5) 
Family’s recommendation 26 (65.0) 
Provide information to children 23 (57.5) 
    Respondents with children 22 (71.0) 
Provide information to relatives 14 (35.0) 
Doctor’s recommendation 2 (5.0) 
 
Respondents could choose more than one answer from the listed suggested 
motivations.
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Table 3. Main reaction after testing according to genetic result.  
Emotional response n (%) 
Carriers  
Sad/disappointed 5 (22.7) 
Anxious 3 (13.6) 
Surprised 3 (13.6) 
Not surprised 4 (18.2) 
Upset 4 (18.2) 
Proactive 3 (13.6) 
Non-carriers  
Happy/relieved 18 (100.0) 
 
This was a free-response question and similar responses were categorized together in 
frequency tables. 
 
Table 4. Concerns relating to positive genetic test result. 
Concern n (%) 
Loss of vision 10 (45.5) 
Impact on health insurance 5 (22.7) 
Transmission to children 3 (13.6) 
Efficacy of glaucoma treatments 2 (9.1) 
Travelling distance to clinic when 
living in rural area 
1 (4.5) 
 
This was a free-response question and similar responses were categorized together in 
frequency tables 
 
